There’s a new way to kill tumors
by eradicating the immune suppressive nature of the TME
IO Biotech is a Phase 3 company leading the way
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win® technology platform.
Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.